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Abstract
OBJECTIVES—Pediatric HIV infection is a growing problem in most regions of the world. Data
on the effects of HIV on the neurodevelopment of children in resource-poor settings are scarce but
necessary to guide interventions. The purpose of this study was to compare the neurodevelopment
of preschool-aged HIV-infected, HIV-affected (HIV-uninfected AIDS orphans and HIV-uninfected
children whose mother had symptomatic AIDS), and healthy control children in Kinshasa,
Democratic Republic of Congo.
METHODS—Thirty-five HIV-infected, 35 HIV-affected, and 90 control children aged 18 to 72
months were assessed by using the Bayley Scales of Infant Development II, Peabody Developmental
Motor Scales, Snijders-Oomen Nonverbal Intelligence Test, and Rossetti Infant-Toddler Language
Scale, as appropriate for age.
RESULTS—Overall, 60% of HIV-infected children had severe delay in cognitive function, 29%
had severe delay in motor skills, 85% had delays in language expression, and 77% had delays in
language comprehension, all significantly higher rates as compared with control children. Young
HIV-infected children (aged 18–29 months) performed worse, with 91% and 82% demonstrating
severe mental and motor delay, respectively, compared with 46% and 4% in older HIV-infected
children (aged 30–72 months). HIV-affected children had significantly more motor and language
expression delay than control children.
CONCLUSIONS—The impact of the HIV pandemic on children’s neurodevelopment extends
beyond the direct effect of the HIV virus on the central nervous system. AIDS orphans and HIV-
negative children whose mothers had AIDS demonstrated significant delays in their
neurodevelopment, although to a lesser degree and in fewer developmental domains than HIV-
infected children. Young HIV-infected children were the most severely afflicted group, indicating
the need for early interventions. Older children performed better as a result of a “survival effect,”
with only those children with less aggressive disease surviving.
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THE HIV/AIDS EPIDEMIC continues to affect millions of children in developing countries,
because access to prevention of mother-to-child transmission interventions and highly active
antiretroviral treatment (HAART) have not yet reached wide coverage in many high HIV
prevalence countries. At the end of 2006, an estimated 2.3 million children were living with
HIV/AIDS and 530 000 were newly infected with HIV in 2006. The Democratic Republic of
Congo (DRC) is home to an estimated 120 000 children living with HIV and 680 000 AIDS
orphans.1
Since the first reports of pediatric AIDS in the 1980s, delayed neurodevelopment has been a
well-recognized complication of HIV disease.2,3 Experiences from the United States and
Europe indicate that HIV central nervous system (CNS) involvement can occur before there
is significant immunosuppression and may be the first AIDS-defining illness in as many as
18% of pediatric patients.4,5 HIV-related encephalopathy can present as static or progressive
HIV encephalopathy, with microcephaly, delay or loss of developmental milestones (motor,
mental and language), and pyramidal tract symptoms.6 Before HAART was introduced,
encephalopathy was reported in 35% to 50% of children with a diagnosis of AIDS in the United
States.5,7–10 HAART can prevent and reverse encephalopathy present at the time of HAART
initiation.11,12 Consequently, the introduction of HAART in the United States has reduced the
incidence of encephalopathy to <2%.11
Results from studies in the United States and Europe may not be generalizable to the population
in Africa and other resource-poor settings, where there is also a high prevalence of malnutrition,
malaria, tuberculosis and other opportunistic infections, and substantially different child-
rearing environments. Despite that sub-Saharan Africa is home to 80% of HIV-infected
children, there is a paucity of data on neurodevelopment from this region. Results of the few
studies demonstrated HIV-related CNS involvement at similar or higher prevalence rates
compared with the United States. A study of Rwandan children 6 months to 2 years of age
observed that 40% of HIV-infected children had an abnormal neurodevelopmental examination
at 18 months compared with only 5% of HIV-exposed uninfected children, and gross motor
scores were significantly lower at all studied time points in HIV-infected children.13 A study
in the DRC documented developmental impairment in both asymptomatic HIV-infected
children and HIV-exposed, uninfected children compared with control children, supporting the
idea that there may be an environmental component compounding the delay as a result of the
presence of HIV in the CNS.14 A study of Ugandan children from birth to 2 years found that
HIV-infected infants not only scored lower in mental and motor development but also
demonstrated greater deceleration in their rate of motor development compared with HIV-
exposed, uninfected infants and a control group.15 At school age (6–12 years), these HIV-
infected children experienced poorer growth and more acute illness but were not significantly
different in their neurologic, motor, and psychometric development compared with control
children, suggesting that children with more aggressive encephalopathy may not survive to
school age in the absence of HAART.16 A study of children in Tanzania found that the
developmental scores decreased with increasing age, suggesting a cumulative risk for poor
neurodevelopment caused by HIV, poverty, and the stress placed on families who care for HIV-
infected individuals.17 This study aimed to examine the effects of the HIV epidemic on the




A total of 160 children aged 18 to 72 months were enrolled in the study between November
2004 and September 2005: 35 HIV-infected children; 35 uninfected, affected children; and 90
uninfected healthy control children. HIV-infected children (group 1) were identified through
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a pediatric HIV care and treatment program. Children were enrolled in the study at the time
they presented to the HIV care and treatment program. Consequently, children were ART-
naive or had received <1 week of HAART before neurodevelopmental assessment. HIV-
affected children (group 2), defined as HIV-uninfected maternal AIDS orphans or HIV-
uninfected children living with a mother with symptomatic AIDS, were recruited through a
nongovernmental organization for social support to HIV-infected women in Kinshasa. Control
children (group 3) were of HIV-uninfected healthy mothers and healthy fathers, with healthy
defined as the absence of an illness that interferes with daily activities. Control children were
identified at a maternity clinic with prevention of mother-to-child transmission of HIV
activities. The control group was composed of 5 boys and 5 girls for every 6-month age class
between 18 and 72 months. Children were excluded from the study when they presented with
an acute infectious disease at the time of planned neurodevelopmental assessment. The study
was approved by the institutional review boards of the Schools of Public Health of the
University of North Carolina at Chapel Hill and the University of Kinshasa.
Data Collection
Clinical and anthropometric data, socioeconomic status, and health status of the parents were
collected at enrollment. Socioeconomic status was assessed by inquiring about access to
running water, number of bedrooms, income, type of toilet, adequacy of income, and food.
For younger children (aged 18–29 months), the Bayley Scales of Infant Development, 2nd
Edition, was used to assess mental (Mental Development Index) and motor development
(Psychomotor Development Index), and the Rossetti Infant-Toddler Language scale (1990
version) was used to evaluate language development. Older children (aged 30–72 months were
assessed using the Peabody Developmental Motor Scales (2nd edition), the Snijders-Oomen
Nonverbal (SON) Intelligence test 2½–7 (abridged 2004 version including situations, mosaics,
categories, and patterns), and the Rossetti Infant-Toddler Language scale for children up to 36
months of age. Language development was not assessed for children who were older than 36
months. Assessment tools were translated into Lingala, the local language.
Neurodevelopmental assessment was performed by 1 pediatrician and 2 physiotherapists, who
had received an 8-week neurodevelopmental assessment training (Bayley, Rossetti) in Cape
Town, South Africa. In addition, the pediatrician (Dr Mupuala) had received training that
consisted of 108 hours in neurodevelopmental testing procedures (Bayley, Peabody, and SON),
140 hours of neuropediatric consultations, and 72 hours of consultations at care institutions for
children with neurodevelopmental disorders in Leuven, Belgium.
Data Analyses
Group means were calculated for the norm-referenced Bayley Scales of Infant Development-
II, Peabody, and SON. The neurodevelopment of children was classified as “no delay” when
their score fell within 1 SD of the mean standardized score, (100) “moderate delay” when they
scored between 1 and 2 SDs from the mean (ie, 70–84), or “severe delay” when they score <2
SDs (≤69). For the Rossetti test, we computed a global baseline and ceiling age level (ie, the
oldest 3-month age level at which the child mastered all items in language expression and
language comprehension). Children were considered to have “no delay” when their score fell
within their 3-month age category or when they scored in the 3-month age category below their
age. They were considered “delayed” in their language development when they scored ≥2 3-
month categories below their age.
Group means were compared by using t tests or the nonparametric Wilcoxon ranked-sum tests.
The χ2 test for contingency tables and Fisher’s exact tests compared categorical and event
frequency data. Analysis was conducted by using SAS 8.2 (SAS Institute, Inc, Cary, NC).
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Demographic, Socioeconomic, and Clinical Characteristics
The mean age of participants was 43.7 months and did not differ significantly a groupings
(Table 1). Approximately 50% of children were male. None of the control children were
orphans (by inclusion criteria). Among HIV-infected children, 28.6% were maternal and 40%
were paternal orphans. Among affected children, 35.5% were paternal and 8.6% were maternal
orphans. Malnutrition and stunting, defined as z scores >2 SDs below the mean weight for age
and height for age, was significantly more prevalent among HIV-infected and HIV-affected
children, but even 16.7% of control children were malnourished, reflecting the high level of
poverty in the DRC. HIV-affected children and HIV-infected chil-dren had a significantly
poorer socioeconomic living standard compared with control children. The proportion of
children aged <60 months with microcephaly, defined as head circumference less than the third
percentile, was the highest among HIV-infected children (11.1%), compared with 6.7% among
HIV-affected children and 1.4% among control children (Table 1).
Neurodevelopment of Control Children: Comparison With Normative Reference Population
Mean standardized test scores of 70 healthy control children 18 to 29 months of age were 85.3
(SD: 18.0) for the Bayley Mental Development Index and 94.1 (SD: 13.1) for the Bayley
Psychomotor Development Index. The mean standardized test scores for the 20 healthy control
children 30 to 72 months of age were 84.6 (SD: 22.4) for the SON and 99.2 (SD: 7.9) for the
Peabody. Compared with the normative reference population (1700 children from the United
States for the Bayley, 2003 children from the Unites States for Peabody, and 1124 children
from the Netherlands for SON), these mean scores were significantly lower for mental
development (P < .0001 for Bayley Mental Development Index and SON) but similar for motor
development (P = .08 for Bayley Psychomotor Development Index and 0.7 for Peabody).
Both moderate (26.7%) and severe (24.4%) delay in mental development was observed, and
mental delay was more frequent in older children. In contrast, severe motor delay was not
observed among control children, and moderate motor delay was present in 7.8% and was more
frequent among young children (aged 18–29 months) than older children (30–72 months), with
25% and 2.9% moderate motor delay, respectively (Table 2). Among the children tested for
language development (aged 18–36 months), delay in language comprehension and language
expression was found in 12.9% (Table 3).
Mental Development in HIV-Infected and HIV-Affected Children
Performance on the assessment of mental development was significantly poorer among HIV-
infected children compared with control children (Table 2). Severe delay was present in 60%
of HIV-infected and 40% of HIV-affected children. Severe mental delay was again more
frequently observed among younger HIV-infected children, with 90.9% of HIV-infected
children aged 18 to 29 months presenting with severe delay compared with 46% among HIV-
infected children aged 30 to 72 months.
Motor Developmental in HIV-Infected and HIV-Affected Children
Severe delay in motor development was observed in 28.6% of HIV-infected and 14.3% of HIV-
affected children, and moderate delay was present in 40% of HIVinfected and 14.3% of HIV-
affected children (Table 2). Motor delay was more prevalent among younger children (aged
18–29 months), with 81.8% of HIV-infected and 38.5% of HIV-affected young children
presenting with severe delay, compared with only 4% of older HIV-infected and 0% of HIV-
affected children.
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HIV-infected children 18 to 36 months of age demonstrated significantly higher rates of delay
in language expression (84.6%) and language comprehension (76.7%) compared with control
children (P < .0001). Language expression but not language comprehension was delayed in
the HIV-affected children compared with the control children (P < .02; Table 3).
DISCUSSION
Moderate to severe delay in mental, motor, and language development was observed in the
majority of HIV-infected children and in a substantial proportion of HIV-affected children.
Young HIV-infected children demonstrated more frequent and more severe delay in mental
and motor development compared with older HIV-infected children.
The frequent delay in neurodevelopment among HIV-infected children was also observed in
the previous studies of African HIV-infected children.13–15,18 Comparison of results between
studies is difficult because of differences in age groups studied and the diversity of
neuroassessment tools used. Two studies that also used the Bayley scales (versions I and II)
observed that, by 18 months of age, severe motor delay was observed among 27% to 30% and
severe mental delay in 26% to 27% of HIV-infected children.15,18
In contrast to previous studies,15,19–21 we observed that mental and not motor delay was most
severely affected by HIV infection. The high prevalence of delay in cognitive development
may in part be attributable to differences in child-rearing practices and lack of exposure to
educational toys and multimedia by African children. This is supported by the high frequency
(24.4%) of severe delay in mental development among the healthy control children, which is
much higher than a 2.2% rate that one would expect if the distribution were similar to that in
the reference population.
In this study, the impact of HIV infection on both mental and motor development was most
pronounced among the younger children. Although we cannot exclude the effect of using
different assessment tools in the 2 age groups, we believe that the observed increased
prevalence of delay in the younger HIV-infected group can most likely be attributed to the
absence of access to HAART before the start of this study. In the absence of HAART, children
with fast progression and more aggressive disease are likely to die before reaching the age of
2.22,23 The older children included in the study may thus represent a group of children with
milder disease. A similar “survival effect” was reported from Uganda, where HIV-infected
children aged 6 to 12 years were no longer different in their neurodevelopment compared with
control children.16
Three other studies also assessed the development of HIV-exposed, uninfected children in sub-
Saharan Africa.13–15 Two studies did not observe significant differences between HIV-
exposed, uninfected children and control children. In contrast to our study, these children were
younger (<2 years of age), and the socioeconomic status and quality of the home environment
of HIV-exposed children was not different from that of control children, indicating that the
living conditions of these children was not substantially affected by HIV. In the remaining
study, HIV-exposed, uninfected children who were aged ≥2 years had a significantly poorer
performance on global cognitive measures but comparable motor performance.14 No data were
presented on the living conditions of these children. In our study, in which children affected
by AIDS in the family were selected, we observed higher frequencies of poor motor, mental,
and language expression development among HIV-affected, seronegative children. The data
suggest that AIDS in the family may lead to poverty, poor health, poor living conditions, and
fewer positive parent– child interactions that are conducive to a child’s neurodevelopment.
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Several limitations to the study should be noted. The sample size was too small to model the
impact of covariates and comorbidities using logistic regression. The cross-sectional nature of
this study did not allow exclusion of factors that may have had an impact on the child’s
neurodevelopment before study assessment. Neurologic imaging and standardized
classification of neurologic examination were not available. Assessment of the language
development was not available for the older children, because we were unable to adapt an
existing tool for use in Lingala. Using the classification as normal, moderate, and severe
neurodevelopmental delay based on US or European norms may have led to misclassification
of children and biased the results to a higher prevalence of mental delay. We chose not to
modify the Bayley assessment tools to make the assessment culturally appropriate because we
were interested in comparisons between groups and preferred to facilitate comparability
between past and future studies in other settings.
CONCLUSIONS
HIV-infected children who presented for care in Kinshasa performed poorly compared with
HIV-affected and control children on assessments of motor, mental, and language
development. HIV orphans and children who were living with parents who had AIDS were
also at increased risk for developmental delay. Compared with control children, they achieved
lower scores for motor development and tended to have slower scores for cognitive
development. Our results suggest that HIV affects the neurodevelopment of children through
both a direct pathway (ie, the presence of HIV in the CNS) and its effect on the child’s living
conditions. The high rate of developmental delay in HIV-infected and HIV-affected children
as compared with control children underscores the need for screening for and prevention of
neurodevelopmental delay at an early age and calls for access to early interventions and
nutritional and care programs for these vulnerable children.24–27
What’s Known on This Subject
In the United States, HIV encephalopathy occurred in 35% to 50% of children with AIDS
before HAART. Results are not generalizable to Africa. Only 6 studies have assessed the
effect of HIV on neurodevelopment in Africa, 5 of infants and 1 of school-aged children.
What This Study Adds
We demonstrate that young HIV-infected children are the most severely affected group,
indicating the need for early intervention. Our study is the first to demonstrate that AIDS
orphans and children who live with parents with AIDS also experience delayed
neurodevelopment.
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